PHAGETECH INC has a total of 24 patent applications. Its first patent ever was published in 1999. It filed its patents most often in Canada, Australia and EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals, biotechnology and measurement are COUNCIL QUEENSLAND INST MEDICAL RES, SUGIYAMA HARUO and INT INST CANCER IMMUNOLOGY INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | Canada | 6 | |
#2 | Australia | 5 | |
#3 | EPO (European Patent Office) | 5 | |
#4 | United States | 4 | |
#5 | WIPO (World Intellectual Property Organization) | 4 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Measurement | |
#4 | Machines |
# | Technology | |
---|---|---|
#1 | Peptides | |
#2 | Medical preparations | |
#3 | Therapeutic chemical compounds | |
#4 | Measuring microorganism processes | |
#5 | Microorganisms | |
#6 | Analysing materials | |
#7 | Unspecified technologies |
# | Name | Total Patents |
---|---|---|
#1 | Pelletier Jerry | 24 |
#2 | Dubow Michael | 24 |
#3 | Gros Philippe | 22 |
#4 | Bergeron Dominique | 7 |
#5 | Dehbi Mohammed | 3 |
#6 | Mccarty John | 3 |
#7 | Gros Phillippe | 2 |
#8 | Dubow Mike | 1 |
Publication | Filing date | Title |
---|---|---|
US2004157314A1 | Inhibitors of Staphylococcus aureus primary sigma factor and uses thereof | |
US2004137516A1 | DNA sequences from staphylococcus aureus bacteriophage 44AHJD that encode anti-microbial polypeptides | |
CA2433386A1 | Compositions and methods involving an essential staphylococcus aureus gene and its encoded protein staau_r9 | |
EP1345960A2 | Compositions and methods involving an essential staphylococcus aureus gene and its encoded protein staau-r4 | |
EP1340079A2 | S. aureus protein staau-r2, gene encoding it and uses thereof | |
EP1242611A2 | Compositions and methods involving an essential staphylococcus aureus gene and its encoded protein | |
US6376652B1 | Compositions and methods involving an essential Staphylococcus aureus gene and its encoded protein | |
CA2353563A1 | Development of novel anti-microbial agents based on bacteriophage genomics |